11:30 am – 12:30 pm Saturday, October 30

Stopping the Flow: Management of Heavy Menstrual Bleeding and Menstrual Concerns in Adolescent Females with Bleeding and Clotting Disorders (226)

Heavy menstrual bleeding (HMB) and dysmenorrhea are common complaints among adolescent females (O’Brien, 2018). For females with underlying bleeding and clotting disorders, managing their menstrual bleeding can provide challenges unique to their stages of life.

Read more...
Speaker:
Elizabeth Vessey, NP
CNE Hours
1
3:30 – 4:30 pm Friday, October 29

Hot Topics in Pediatric Oncology: Updates from the Children’s Oncology Group (C217)

coglogoImprovements in patient care occur when new research findings are moved into practice. The average length of time for this translation, however, is 17 years. Within the past 3 years, the Children’s Oncology Group (COG) has produced 248 publications (about 83 per year).

Read more...
5:00 – 6:00 pm Thursday, October 28

Lighting the Way in COG with MATCH: Targeted Therapies in Pediatric CNS Tumors (C211)

coglogoPediatric MATCH (Molecular Analysis for Therapy Choice) is a joint effort between the National Cancer Institute (NCI) and Children’s Oncology Group (COG) matching targeted therapies to specific tumor genomic sequencing in patients with relapsed or refractory solid tumors, non-Hodgkin lymphomas, brain tumors, and histiocytic disorders.

Read more...
5:00 – 6:00 pm Thursday, October 28

Paper Presentation: Child/Adolescent Cancer Treatment Experience — Do CSF Biomarkers Relate to Measures of Cognitive Function in Children During Maintenance Therapy for Leukemia? (210-3)

Children treated for acute lymphocytic leukemia (ALL) receive central nervous system–directed chemotherapy, which is a known risk factor for cognitive dysfunction. ALL chemotherapy treatment is also associated with changes in biomarkers of inflammation and oxidative stress, which may underlie changes in neurocognitive functioning.

Read more...
5:00 – 6:00 pm Thursday, October 28

Paper Presentation: Child/Adolescent Cancer Treatment Experience — Analysis of AYA Cancer Patient Priority Symptoms Using Text Mining Software (210-2)

The symptoms associated with cancer treatment are a major concern for the adolescent and young adult (AYA) population. Understanding these distinct symptom experiences, especially AYAs' priority symptoms—those that take the forefront of a patient’s concern—can support healthcare providers in providing personalized care.

Read more...
Speaker:
Kylie Bethards
CNE Hours
1
5:00 – 6: 00 pm Thursday, October 28

Paper Presentation: Child/Adolescent Cancer Treatment Experience — Qualitative Content Analysis of Daily Journaling by Children with Cancer Using a Game-Based App (210-1)

The consequences of cancer persist beyond the clinical setting. Resources to assess the child’s quality of life and markers of well-being outside of the clinical setting can support a more personalized approach to care. Color Me Healthy is a new, game-based symptom assessment app that was co-designed by children with cancer and pediatric oncology clinicians.

Read more...
Speaker:
Kaitlyn Fox, BSN RN
CNE Hours
1

Pediatric Chemotherapy and Biotherapy Instructor Course (002)

The APHON Pediatric Chemotherapy and Biotherapy Instructor Course is designed for any nurse who has completed the provider course and meets the qualifications to be trained to teach the course. This course provides general instruction in adult education, guidance in the planning of lectures based on the APHON program content, and instruction in administering the provider exam. Upon successful completion, nurses return to their institutions as recognized APHON Pediatric Chemotherapy and Biotherapy Instructors who are able to provide ongoing instruction and education to other registered nurses.

Read more...
2:15 – 3:15 pm Saturday, October 30

Perspectives on supporting schooling for children with cancer: Findings from two PCORI Engagement Projects (230)

Education is an important social determinant of health, and treatment for childhood cancers can result in long-term neurocognitive effects (deficits in processing speed, working memory, executive function, and attention), which are associated with reduced educational attainment, employment, and ability to live independently.

Read more...
3:30 – 4:30 pm Friday, October 29

Joint Topic: Rarer H/O Diagnoses — Manifestations and Management of Langerhans Cell Histiocytosis (220-2)

Langerhans cell histiocytosis (LCH) is a rare multisystem disease that arises from the myeloid dendritic cells and often presents as common childhood ailments (Zinn, Grimes, Lin, Eckstein, Allen, & McClain, 2016). Histiocytes invade many different organ systems, including the lymph nodes, lungs, thymus, liver, spleen, bone marrow, and/or the central nervous system (McClain, 2019).

Read more...
3:30 – 4:30 pm Friday, October 29

Joint Topic: Rarer H/O Diagnoses — Clinical Pearls of Sirolimus Management for Vascular Anomalies (220-1)

Vascular anomalies are a group of disorders and are categorized as either vascular tumors or malformations. Vascular malformations can proliferate and expand, and have clinical sequelae such as chronic pain, disfigurement, infection, coagulopathy, impaired organ function, and decreased quality of life.

Read more...
Speaker:
Breanne Roche, DNP RN CPNP-PC CPHON®
CNE Hours
1
RX Hours
0.33
Subscribe to this RSS feed